Vaccines are planning to delete its shared shares from the stock market on the NASDAC – vaccine (OTC: VCNX)

Rothsters, New York, 07 March, 2025 (Globe Newswire) – Vaccinex, Inc. Vcnx (“Vaccines” or “The Company”), a biotechnology company in the clinical stage a pioneer in a different approach to treating neurological degeneration by preventing Astrogliosis and Neuronflamation by inhibiting Sema4D, today, was notified by the Nasdaq Market (“” Nasdaq “) from its decision to make buses, both,” regular shares “, From Nasdak. Trading on regular stocks has been suspended on the Nasdaq Stock Exchange since December 18, 2024.

Vaccinex plans to submit a model 25 to the Securities and Stock Exchange Committee in or about 17 March 2025 to remove its shared shares from the listing on the Nasdaq Stock Exchange.

The company’s decision to calculate its receipt of the notice dated December 16, 2024, that the NASDAC’s listening session has decided to write off the company’s securities from the Nasdaq Stock Exchange, and the subsequent suspension of trading. Nasdak could have presented the 25 -time model.

The company plans to continue to focus on developing its main product, Pepinemab, to treat Alzheimer’s and cancer through partnerships, grants and other financing methods.

About Vaccinex Inc.

Vaccinex, Inc. By manufacturing a different approach to the treatment of progressive neurological degenerative diseases and cancer by inhibiting the 4D (sema4D). The company’s main drug candidate, Pepinemab, blocks Sema4D, a strong biological respondent believed to lead to the destruction of inflammation in chronic diseases in the brain and prevents infiltration and activating immune cells in tumors. Pepinemab has been studied as a single treatment in the study of the 1B/2 AD stage in Alzheimer’s disease, and the company previously published the promising second stage data in Huntington’s disease. The vaccine believes that Pepinemab can also be an important contributor to compound therapy in M. In oncology, Pepinemab is evaluated in partnership with Keytruda® in the study of 1B/2 Keynote-B84 in the frequent or metallic neck cancer (HNSCC) and in a combination with BavNCIO® in the study of the 1 B/2 in patients with a metaphysical gaseous blocker (PDAC). The clinical program for tumors also includes many studies sponsored by researchers in solid tumors, including breast and skin cancer.

Vaccinex has commercial rights and global development for Pepinemab and is a sponsor to study Keynote-B84 that is implemented in cooperation with Merck Sharp & Dohme Corp, a company belonging to Merck and Co, Inc. Kenilworth, NJ, USA.

Keytruda is a registered brand for Merck Sharp & Dohme, a Merck & Co. Inc. , Kenilworth, NJ, USA. BavNCio®/Aveleumab is provided by Merck Kgaa, DarMstadt and Germany, previously as part of an alliance between Merck Kgaa, DarMstadt, GERMANY and Pfizer.

About Pepinemab

Pepinemab is a monochromatic body IGG4 designed to prevent Sema4D, which can be associated with Plexin-B1 receptors to create a breakdown in a light cellular structure in cellular cells in immune cells in immune cells. Pepinemab seems well with a favorable profile of safety in multiple clinical trials in various nervous indicators and cancer.

Looking data forward

To the extent that the phrases mentioned in this press statement are not descriptions of historical facts related to Scuinex, INC. (“Vaccines”, “We”, “We”, or “Our”), may be aspiration data that reflects current beliefs and expectations. These phrases include, but not limited to, the data set by words such as “May”, “Will”, “Will”, “” plans “and” expectation “or” similar expressions or their negatives (as well as other words and expressions that refer to events, conditions or future circumstances). This data includes, among other things, those related to the expected time of the account from Nasdak and the expected benefits of deletion. These phrases are based on our current expectations and beliefs and are subject to a number of factors and doubts that can cause actual results materially from those described in aspecting data. With the exception of what is required under the law, we do not assume any commitment to update these aspirations. For more discussion on these factors and other factors that can cause future future results from any aspective statement, see the section titled “Risk Factors” in our periodic reports submitted to the Securities, Exchanges Committee, other risks and suspicions described in the latest annual currency report on the 10-k and SEC note.

Investor contact
Elizabeth Evans, PhD
Senior Operating Operations, Vaccinex, Inc.
(585) 766-2033
EEVANS@vaccinex.com